A team of researchers has discovered a new biomarker that can be used to identify aggressive thyroid cancer and predict outcomes for patients. "Our study shows, for the first time, a key biomarker that can be used in diagnostic, prognostic and therapeutic strategies for the future management of thyroid cancer," said endocrinologist Paul Walfish, Alex and Simona Shnaider Research Chair in Thyroid Oncology at Mount Sinai Hospital and the senior author of the study. Story